These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 16094663)
1. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Ladd CO; Newport DJ; Ragan KA; Loughhead A; Stowe ZN Depress Anxiety; 2005; 22(2):94-7. PubMed ID: 16094663 [TBL] [Abstract][Full Text] [Related]
2. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. Amsterdam JD; Shults J J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727 [TBL] [Abstract][Full Text] [Related]
3. Escitalopram for perimenopausal depression: an open-label pilot study. Freeman MP; Hill R; Brumbach BH J Womens Health (Larchmt); 2006 Sep; 15(7):857-61. PubMed ID: 16999641 [TBL] [Abstract][Full Text] [Related]
4. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Malhi GS; Ng F; Berk M Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778 [TBL] [Abstract][Full Text] [Related]
5. [Treatment with venlafaxine extended release for climacteric women with depression or anxiety diagnosis. An open-label study]. Iglesias C; Pato E; Ocio S; Ortigosa JC; Santamarina S; Merino MJ; Alonso MJ; Fernández L; Alonso JL; Rodríguez L Actas Esp Psiquiatr; 2009; 37(3):137-42. PubMed ID: 19533425 [TBL] [Abstract][Full Text] [Related]
6. [Gender differences in clinical profile, response and remission of depressive patients treated with venlafaxine extended release]. Roca M; Baca E; Prieto R; García-Calvo C Actas Esp Psiquiatr; 2008; 36(2):82-9. PubMed ID: 17597432 [TBL] [Abstract][Full Text] [Related]
7. Venlafaxine extended-release in patients older than 80 years with depressive syndrome. Baca E; Roca M; Garcia-Calvo C; Prieto R Int J Geriatr Psychiatry; 2006 Apr; 21(4):337-43. PubMed ID: 16570327 [TBL] [Abstract][Full Text] [Related]
8. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS Menopause; 2006; 13(5):780-6. PubMed ID: 16894334 [TBL] [Abstract][Full Text] [Related]
9. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. Simon JS; Aguiar LM; Kunz NR; Lei D J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430 [TBL] [Abstract][Full Text] [Related]
14. Self-reported anxiety, depressive, and vasomotor symptoms: a study of perimenopausal women presenting to a specialized midlife assessment center. Seritan AL; Iosif AM; Park JH; DeatherageHand D; Sweet RL; Gold EB Menopause; 2010 Mar; 17(2):410-5. PubMed ID: 20216277 [TBL] [Abstract][Full Text] [Related]
15. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Hsiao CC Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529 [TBL] [Abstract][Full Text] [Related]
16. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Baca E; Garcia-Garcia M; Porras-Chavarino A Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):57-65. PubMed ID: 14687858 [TBL] [Abstract][Full Text] [Related]